Multiple Sclerosis Clinical Trials in Phoenix

Showing 461-480 of 490 trials

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

NCT00109655

The main purpose of this research study is to evaluate the safety and dosing of CG0070.

Carcinoma, Transitional CellBladder Neoplasms

Cell Genesys75 participantsStarted Apr 2005

Phoenix, Arizona, United States • San Francisco, California, United States • Billings, Montana, United States +7 more locations

COMPLETEDPhase 1< 1 mile

Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

NCT00103974

This research study is being done to evaluate the safety of BHT-3009 alone and when combined with atorvastatin (Lipitor) in patients with multiple sclerosis (MS).

Multiple Sclerosis

Bayhill Therapeutics30 participantsStarted Jul 2004

Phoenix, Arizona, United States • Los Angeles, California, United States • Vancouver, British Columbia, Canada +1 more locations

TERMINATEDPhase 3< 1 mile

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00290017

This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.

Carcinoma, Non-Small-Cell LungLung CancerNeoplasms, Lung+1 more

Point Therapeutics400 participantsStarted Feb 2006

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Hot Springs, Arkansas, United States +98 more locations

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Multiple Sclerosis Trials in Other Cities

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

A Phase III Trial For Patients With Metastatic Breast Cancer

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients

A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Other Conditions in Phoenix